Cartesian Therapeutics, Inc. (RNAC)
$6.57-6.01%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $193M
- Beta
- 0.65
- P/E (TTM)
- -1.11
- Short % float
- 17.46%
- Days to cover
- 12.6
- SI change
- +2.9%
- 1W
- -2.67%
- 1M
- -18.28%
- vs SPY 1W
- -2.53%
- vs SPY 1M
- -20.79%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 5
- GROWTH
- 0
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC84.8%
REV YoY-
ROE141.4%
EPS YoY-
ROA-48.3%
GROSS-766
OP-6680
NET-10422
[VALUATION]
P/E TTM-1.11
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B-1.55
P/FCF-
EV/EBITDA-0.69
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO7.48
ND/EBITDA-
BETA0.65
Company news
FAQ
- What is LOPJLB’s current signal on RNAC?
- LOPJLB’s latest quantitative signal on Cartesian Therapeutics, Inc. (RNAC) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is RNAC in?
- Cartesian Therapeutics, Inc. (RNAC) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cartesian Therapeutics, Inc. (RNAC) do?
- Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The companyâs lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune dis…